AIRLINK 66.00 Increased By ▲ 0.80 (1.23%)
BOP 5.65 Increased By ▲ 0.08 (1.44%)
CNERGY 4.56 No Change ▼ 0.00 (0%)
DFML 24.62 Increased By ▲ 0.10 (0.41%)
DGKC 69.50 Decreased By ▼ -0.46 (-0.66%)
FCCL 20.28 Decreased By ▼ -0.02 (-0.1%)
FFBL 29.30 Increased By ▲ 0.19 (0.65%)
FFL 9.82 Decreased By ▼ -0.01 (-0.1%)
GGL 10.04 Increased By ▲ 0.03 (0.3%)
HBL 113.50 Decreased By ▼ -0.75 (-0.66%)
HUBC 128.75 Decreased By ▼ -0.35 (-0.27%)
HUMNL 6.71 Increased By ▲ 0.01 (0.15%)
KEL 4.44 Increased By ▲ 0.06 (1.37%)
KOSM 4.85 Decreased By ▼ -0.04 (-0.82%)
MLCF 36.90 Decreased By ▼ -0.10 (-0.27%)
OGDC 132.55 Increased By ▲ 0.25 (0.19%)
PAEL 22.45 Decreased By ▼ -0.09 (-0.4%)
PIAA 25.60 Decreased By ▼ -0.29 (-1.12%)
PIBTL 6.65 Increased By ▲ 0.05 (0.76%)
PPL 113.50 Increased By ▲ 0.65 (0.58%)
PRL 28.84 Decreased By ▼ -0.57 (-1.94%)
PTC 14.75 Decreased By ▼ -0.49 (-3.22%)
SEARL 57.00 Decreased By ▼ -0.03 (-0.05%)
SNGP 66.30 Decreased By ▼ -0.15 (-0.23%)
SSGC 10.90 Decreased By ▼ -0.08 (-0.73%)
TELE 8.66 Decreased By ▼ -0.14 (-1.59%)
TPLP 11.70 No Change ▼ 0.00 (0%)
TRG 68.30 Decreased By ▼ -0.32 (-0.47%)
UNITY 23.60 Increased By ▲ 0.20 (0.85%)
WTL 1.36 Decreased By ▼ -0.02 (-1.45%)
BR100 7,295 No Change 0 (0%)
BR30 23,957 Increased By 102.4 (0.43%)
KSE100 70,473 Increased By 182.7 (0.26%)
KSE30 23,169 Decreased By -1.5 (-0.01%)
World

EU has not yet ordered more AstraZeneca vaccines, says internal market commissioner

  • Breton said an increase in prices for second generation vaccines could be justified by the extra research required and potential changes to industrial equipment.
Published May 9, 2021

PARIS: The European Union has not yet made any new orders for AstraZeneca vaccines beyond June when their contract ends, European Internal Market Commissioner Thierry Breton said on Sunday.

Breton also said he expected that the costs of the EU's recent order for more doses of Pfizer-BioNTech vaccines would be higher than the earlier versions.

The Commission last month launched legal action against AstraZeneca for not respecting its contract for the supply of COVID-19 vaccines and for not having a "reliable" plan to ensure timely deliveries.

"We did not renew the order after June. We'll see what happens," said Breton, adding that it was "a very good vaccine".

Concerns has risen on potential side-effects of the Anglo-Swedish COVID-19 vaccine.

Europe's medicines regulator said on Friday it is reviewing reports of a rare nerve-degenerating disorder in people who received the shots, a move that comes after it found the vaccine may have caused very rare blood clotting cases.

Breton said an increase in prices for second generation vaccines could be justified by the extra research required and potential changes to industrial equipment.

The European Union signed a new contract with Pfizer-Biontech to receive 1.8 billion doses of COVID-19 vaccines for 2021-2023, to cover booster shots, donations and reselling of doses, the European Commission said on Friday.

"There may be a little extra cost but I will let the competent authorities unveil it in due course," he told France Inter radio.

Comments

Comments are closed.